These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 35726199)

  • 21. Real-world clinical outcomes in patients with multiple myeloma treated with isatuximab after daratumumab treatment.
    Kikuchi T; Tsukada N; Nomura M; Kasuya Y; Oda Y; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Ishida T
    Ann Hematol; 2023 Jun; 102(6):1477-1483. PubMed ID: 37115297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
    Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis.
    Chen H; Chen H; Zhou Y; Xu W; Yu J; Xu Y; Zhou F
    Hematology; 2023 Dec; 28(1):2225342. PubMed ID: 37343159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
    Richardson PG; Beksaç M; Špička I; Mikhael J
    Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
    Banerjee R; Lo M; Martin TG
    Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma].
    Nishimura N; Terui Y; Hatake K
    Rinsho Ketsueki; 2017; 58(8):1006-1013. PubMed ID: 28883263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.
    Arnall JR; Maples KT; Harvey RD; Moore DC
    Ann Pharmacother; 2022 Aug; 56(8):927-940. PubMed ID: 34963325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
    Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
    Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of isatuximab in combination with steroids for the treatment of relapsed/refractory multiple myeloma patients exhibiting only biochemical progression-A single center retrospective study.
    Regidor BS; Jew S; Goldwater MS; Beatty BM; Bujarski S; ElSayed A; Danis R; Kim S; Swift R; Schwartz G; Berenson JR
    Eur J Haematol; 2023 Oct; 111(4):628-635. PubMed ID: 37485542
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal Antibodies in the Treatment of Multiple Myeloma.
    van de Donk NWCJ; Zweegman S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):337-360. PubMed ID: 38151402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [CD38 targeted treatment for multiple myeloma].
    Jelínek T; Mihályová J; Hájek R
    Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
    Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
    Front Oncol; 2020; 10():624661. PubMed ID: 33680948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
    van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
    Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
    Koiwai K; El-Cheikh R; Thai HT; Brillac C; Fau JB; Veyrat-Follet C; Risse ML; van de Velde H; Semiond D; Nguyen L
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):928-940. PubMed ID: 34185964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.
    Franssen LE; Stege CAM; Zweegman S; van de Donk NWCJ; Nijhof IS
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32331242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging antibodies for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
    Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC
    Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.